Purpose: To develop a reproducible laboratory model to simulate a battlefield foveal laser injury and to test potential neuroprotective effects of a single injection treatment that might be administered in a military setting.
Methods: Frequency-doubled 532-nm Nd:YAG laser was used to induce a threshold retinal injury bilaterally in transgenic reporter mice that have fluorescent cones. Intravitreal injection of ciliary neurotrophic factor (CNTF) was then administered to the lasered eye and compared with a contralateral sham injection of saline. The effect on fluorescent cone cell survival was quantified using a confocal scanning laser ophthalmoscope (cSLO), TUNEL assays, and quantitative real-time PCR (qPCR).
Results: At 3 weeks post-laser, cSLO imaging showed that the proportion of surviving cones expressing green fluorescent protein (GFP) was greater in CNTF-treated (54.1 ± 5.15% of baseline count) than in sham-injected eyes (28.7 ± 4.4%), which was accompanied by a reduction in TUNEL-positive cells. This difference in cone survival persisted at the 6-week point (treated, 39.6 ± 3.2% versus sham, 18.0 ± 3.8%). These changes were accompanied by a reduction in TUNEL-positive cells. The Bcl-2/Bax ratio was increased in CNTF-treated eyes at 1 week postlaser exposure relative to controls.
Conclusions: A single intravitreal injection of CNTF protein was shown to improve cone survival when administered immediately after laser exposure. Similar treatments with CNTF might also have a role in attenuating retinal laser damage sustained by combat personnel in the military setting.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1167/iovs.13-11623 | DOI Listing |
Lasers Med Sci
January 2025
Department of Ophthalmology, Ankara University School of Medicine, Ankara, Turkey.
The aim of the study was todescribe the clinical features, optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging in patients with choroidal and retinal tumors. Ninety eyes of 89 patients with treatment-naive macular, midperipheral, and juxtapapillary choroidal and retinal tumors were retrospectively included in the study. All patients underwent a complete ophthalmic examination, B-mode ultrasonography, OCT, and FAF imaging.
View Article and Find Full Text PDFOphthalmol Retina
January 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address:
Purpose: Laser photocoagulation (LPC) has been a traditional treatment for retinopathy of prematurity (ROP). However, intravitreal anti-VEGF agents such as bevacizumab and ranibizumab (IVR) have also been increasingly used. This meta-analysis aims to rigorously compare IVR to LPC in the treatment of ROP.
View Article and Find Full Text PDFBackground And Objective: Sickle cell disease (SCD) is a vascular disease that may affect the retina. This study aimed to evaluate differences in average velocity (AV, mm/s), blood flow (BF, μL/min) and vessel diameter (VD, μm) from the temporal retinal arcades in SCD compared to healthy eyes using Doppler optical coherence tomography (DOCT).
Patients And Methods: A cross-sectional study was conducted between 2021 and 2023.
Ophthalmic Surg Lasers Imaging Retina
January 2025
The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania.
Ophthalmic Surg Lasers Imaging Retina
January 2025
Tractional retinoschisis (TRS) secondary to proliferative diabetic retinopathy (PDR) may be differentiated from tractional retinal detachment (TRD) by its characteristically nonprogressive course. The purpose of the current study was to describe the use of swept-source optical coherence tomography angiography (SS-OCTA) in the diagnosis and monitoring of TRS secondary to PDR. Retrospective, consecutive case series of patients with TRS secondary to PDR are featured.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!